BioNexus Gene Lab said Muthu Meyyappan was appointed chief commercial officer of Fidelion to lead global commercialization and partnerships for the VitaGuard MRD platform. Meyyappan has more than 15 years of experience in precision oncology diagnostics, genomics, and liquid biopsy commercialization. He previously held senior commercial leadership roles at Menarini Silicon Biosystems, Congenica, Variantyx, and QIAGEN. Most recently, he served as global chief commercial officer at Menarini Silicon Biosystems and earlier was chief commercial officer at Variantyx.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001477932-26-001379), on March 17, 2026, and is solely responsible for the information contained therein.